Key facts
- CeQur received two FDA clearances for its insulin delivery devices.
- The clearances are for extended 7-day wear and 1-unit dosing.
- New clinical evidence will be presented at the ADA Scientific Sessions.
CeQur, a company focused on simplifying mealtime insulin delivery for individuals with diabetes, has announced significant advancements. The company has secured two recent FDA clearances for its insulin delivery devices. These clearances pertain to an extended 7-day wear capability and a precise 1-unit dosing increment. Furthermore, CeQur will be presenting new clinical evidence related to these advancements at the upcoming American Diabetes Association (ADA) Scientific Sessions. The company aims for these developments to set a new standard in mealtime insulin management.